Wednesday 17th September - Main Conference Day Two - ET (Eastern Time, GMT-05:00)
- Fouad Atouf - Vice President, Science—Global Biologics, US Pharmacopeia
- Niklas Engler - Global Head and Vice President, Technical Development Portfolio and Projects, F. Hoffmann-La Roche
- Christopher Bravery, Ph.D. - Consulting Regulatory Scientist, Advbiols
- Kat Kozyrytska - Consultant, Cell Therapy Manufacturability Program
- Shashi Murthy, PhD - CTO and Co-Founder, Nanite Inc.
- Pauline Schmit - Senior Scientist, nChroma Bio
- Mahesh Bule - Associate Director, Kite Pharma a Gilead Company
- Amy Shaw - Head of Process and Product Development, Takeda, USA
- Mark Farmery - Chief Development Officer, Anocca AB
- Defining point-of-care manufacturing and decentralized manufacturing
- Scaling with consistency: key elements for global standardization
- Tech & innovation: cutting-edge solutions for safe, efficient, and cost-effective decentralized manufacturing
- Overcoming obstacles to decentralised manufacturing to enable access to approved CGTs
- Differences in systems across decentralized cell therapy manufacturing models - how can we harmonize?
- Standardization vs a modular approach
- Equipment, data, and technologies
- Dialogue and collaboration between developer/practitioner to streamline eventual implementation
- Improving worldwide access: how can local manufacturers and supplier help?
- Real world experience with a decentralized cell therapy manufacturing platforms supporting Phase I/II clinical trials
- Francesca Vitelli, PhD - Former VP Cell Therapy and Viral Vector PD and MSAT, Intellia Therapeutics, Inc
- Ying Cai - MSAT Executive Director, Ultragenyx Pharmaceutical
- Nripen Singh - Head of Process Development, TRD CGT, Novartis
- Vaishali Shukla - Vice President, CGT & API Global Expansion, Eli Lilly and Company
- James Warren, Ph.D. - Senior VP, Global CMC Development, Ultragenyx Pharmaceutical Inc.
- Phillip Ramsey - Senior Vice President, Technical Operations, Sangamo Therapeutics
- Jordan Ball - Sr. Manager, Technology Transfer, Regeneron
Discover how Yokogawa’s BioPilot transforms bioprocessing with seamless digital integration and intelligent automation. By unifying real-time data acquisition and advanced process control, BioPilot empowers scientists to streamline cell culture and purification workflows—enhancing reproducibility, accelerating development timelines, and enabling effective decisions in cell line, media, and process development.
- Soichiro Shimoda - Bioprocess Development Sect. Manager, Yokogawa Electric Corporation
- DirectedLuck® transposase integrates genes at most active genomic sites via epigenetic targeting and delivers highest pool titers with minimal selection pressure.
- Automated clone assessment enables early clone selection based on platform fit and critical product quality parameters.
- Smart automation delivers better, high quality producer clones in shortest time.
- Volker Sandig - Chief Scientific Officer, ProBioGen AG
Explore groundbreaking research, meet the poster presenters and ask your questions.
*For your poster to be entered into the poster competition, please submit your abstract by August 1, 2025 and PDF poster by August 22, 2025*
- Andreas Schaaf - CSO & Managing Director, Eleva GmbH
- Xiaodong Sun - Senior Scientist, Takeda
- Yuxin Liu - Scientist, Cell Culture Platform, Sanofi
- Shu Yang - Senior Scientist, Pfizer
- Edwin Shen - Principal Scientist, Pfizer
- Zhuangrong Huang - Senior Staff Engineer, Takeda
- Naveen Singh - Principal Scientist II, Process Development, Gilead
- Crystal Thomas - Principal Scientist, Purification Process Development, Sanofi
- Kate Zhao - Scientist I, Upstream Process Development, Alexion, AstraZeneca Rare Disease
- Kelvin Lee - Institute Director, NIIMBL
- Mark Duerkop - Chief Executive Officer, Novasign, Austria
- Elisabeth Krug - Executive Director, BRD Analytical Development, Eli Lilly & Company
- Callum Chapman - Senior Director, Product Quality, AstraZeneca
- Kristy Wood, PhD - SVP, Technical Operations, Intellia Therapeutics
- Devyn M. Smith - Chief Executive Officer, Arbor Biotechnologies
- Shawn (Xueyuan) Wang - Director, Process Development, Kite Pharma
- Wonjong Si - Director of Cell Therapy Process Development, Bayer
- Improvements and innovations in cell line development & engineering to increase yields for gene therapies
- Application of producer cell lines to lower transfection vector costs: Data for large scale use of stable cell lines
- Scalability of producer cell lines? Case studies on experiences at larger scales
- Huize Yan - Process Development Scientist, Spark Therapeutics
Join leading experts for BioProcess Insider's comprehensive analysis of the current bioprocessing landscape, emerging trends, and future directions shaping biopharmaceutical manufacturing and development.
- Dan Stanton - Editorial Director, Informa Connect Life Sciences
- John Cox - CEO, Dyne Therapeutics
- Jared Auclair, PhD - Dean College of Professional Studies and Director of Bioinnovation, College of Science at Northeastern University
As upstream bioprocessing intensifies, efficient cell separation is key. This presentation highlights a collaboration between ProBioGen AG and GEA, showcasing the kytero® Single Use Pharma Separator. Supporting both harvest and perfusion applications, this disk stack centrifuge delivers high separation efficiency at elevated cell densities, reduces process complexity, and integrates seamlessly into intensified CHO-based workflows from pilot to commercial scale.
- Nathalie Rigal - Head of Upstream Process Development, ProBioGen AG
The realization of patient-driven benefits from complex biologics remains a significant challenge, primarily due to high cost of goods. ProteoNics addresses this bottleneck by integrating its proven 2G UNic® vector technology with advanced transposon systems to achieve sky-high expression titres.
This powerful combination, along with further improvements in development and manufacturing, paves the way for next-generation biologics to be produced at significantly lower cost. Selection can be completed in just two weeks, yielding bulk pools enriched with high-expressing clones. This enables a faster, more efficient, and more robust clone selection process, accelerating timelines and reducing costs without compromising quality.
- Maurice Van Der Heijden - Senior Director, Research and Development, ProteoNic
- Lorena Pena - Scientist, Bristol-Myers Squibb
- Fernanda Sobreira - Associate Principal Scientist, Merck
- Lorraine Peters - Associate Scientist, AstraZeneca
- Coral Fung Shek - Process Development Senior Scientist, Amgen
- Xuan Han, PhD - Senior Scientist, Amgen
- Stefano Menegatti - Professor, Chemical and Biomolecular Engineering, North Carolina State University
- Chase Herman, Ph.D. - Investigator, GSK
- Gregory Zarbis-Papastoitsis, Ph.D - Chief Process and Manufacturing Officer, Ankyra
- Jack Greene - Chief Technical and Manufacturing Officer, JucaBio
- Arvind Srivastava, Ph.D. - Senior Vice President, ThirdArcBio
- Anand Srinivasan - Vice President of Technology and Innovations, and Head of the Center for Innovations and Biodesign, BioBridge Global
- Weiyi Li - Senior Manager, LNP Formulation, Prime Medicine, Inc.
- Shashi Prajapati - Director, Cell & Gene Therapies Analytical Development, Vertex Pharmaceuticals
- Lena Yang - Senior Scientist, Cell Therapy Analytical Development, Takeda
- Therese Choquette - Head of Analytical and Translational Sciences, Tigen Pharma
- David Dobnik - Research Councillor, National Institute of Biology
- Hunter Reese - Scientist II, Asklepios Biopharmaceutical
- Junfen Ma - Head of Genomic Medicine Purification Process Development, Sanofi
How Diverse Leadership Drives Breakthrough Innovation
In an industry built on scientific breakthroughs, our greatest innovation opportunity may be unlocking the full potential of diverse talent. While life sciences has made progress in improving diversity and hiring practices, the real advantage lies in creating inclusive pathways to leadership that harness different perspectives, experiences, and problem-solving approaches to drive the next generation of medical breakthroughs.
Discussion Points:
- Innovation Requires Inclusion
- How diverse leadership teams consistently outperform in R&D outcomes
- The competitive risk of homogeneous leadership in a global market
- Innovation Barriers
- Traditional career pathways limit the diversity in decision-making roles and the resulting innovation cost
- Why inclusive cultures are essential for creative risk-taking and breakthrough thinking
- Rewriting the Leadership Roadmap
- Creating pathways that value diverse experiences and non-linear career journeys and recognizes different styles and strengths
- Building mentorship programs that actively push diverse talent into decision-making positions
- The Future of Biotech Leadership
- Building organizations where innovation and inclusion are inseparable
- Measuring success beyond diversity metrics to innovation outcomes
- Dianne Keen Kim - President, Women in Bio
- Nicola Ambler - Co-Founder, CGT Circle
- Alicja Januszewicz - Former Head of HR, Marengo Therapeutics
A diverse and inclusive workforce is essential to the future of the life sciences industry, but too often, access to careers in this field remains out of reach for talented students from underrepresented backgrounds. Project Onramp is changing that by connecting Pell Grant-eligible undergraduates with paid summer internships that open doors to real-world experience, professional networks, and long-term career pathways. This panel will highlight how the program is building a stronger, more inclusive industry through partnerships with companies and students, featuring insights from interns, alumni, and host employers.
Explore groundbreaking research and meet the poster presenters with your questions.
*For your poster to be entered into the poster competition, please submit your abstract by August 1, 2025 and PDF poster by August 22, 2025*
- Song Zhiwei - Senior Principal Scientist, Nexa Biologics
- Jindou Shi - PhD Student, GSK Center for Optical Molecular Imaging, UIUC
- Yingnan (Michael) Si - Scientist, Sanofi
- Charles Sardonini, PhD - Consultant to the Biotechnology Industry, Sardonini Consulting, LLC
- Naveen Singh - Principal Scientist II, Process Development, Gilead
- Kabir Dhingra - Senior Scientist, Merck
- Regina Au - CEO, New Product Planning/Strategic Planning, BioMarketing Insight
- Siu-Man (Kelvin) Lau - Principal Engineer, Abbvie
- Hao Zhang - Sr. Principal Scientist, Amgen
- William Whitford - Founder, Oamaru BioSystems
- Shankar Swaminathan, PhD - Team Lead, Associate Director Drug Product Development, Astellas Institute for Regenerative Medicine
- Jeff Masten - Senior Vice President CMC, Secretome Therapeutics
- Matthew Provencal - Executive Director Gene Therapy BDS Manufacturing, Sarepta
- Shawn Roach - Associate Principal Consultant, Regulatory CMC, Halloran
- Mariska ter Haak - Senior Director Analytical Development, IN8bio
- Dong Xu, Ph.D. - Associate Director, Cell Therapy Analytical Development, TScan Therapeutics
- Dana Schreffler - Sr. Manager QC Viral Safety, Regeneron
- Parag Kumthekar - Gene Therapy Downstream Process Development Lead, UCB Pharma
Join us for a compelling discussion featuring accomplished Latino leaders in biotechnology as they explore the critical importance of diversity in driving innovation, addressing health disparities, and creating a more inclusive industry landscape.